172 related articles for article (PubMed ID: 27558972)
1. TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models.
Guiho R; Biteau K; Grisendi G; Taurelle J; Chatelais M; Gantier M; Heymann D; Dominici M; Redini F
Int J Cancer; 2016 Dec; 139(12):2802-2811. PubMed ID: 27558972
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo discrepancy in inducing apoptosis by mesenchymal stromal cells delivering membrane-bound tumor necrosis factor-related apoptosis inducing ligand in osteosarcoma pre-clinical models.
Guiho R; Biteau K; Grisendi G; Chatelais M; Brion R; Taurelle J; Renault S; Heymann D; Dominici M; Redini F
Cytotherapy; 2018 Aug; 20(8):1037-1045. PubMed ID: 30093324
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas.
Grisendi G; Spano C; D'souza N; Rasini V; Veronesi E; Prapa M; Petrachi T; Piccinno S; Rossignoli F; Burns JS; Fiorcari S; Granchi D; Baldini N; Horwitz EM; Guarneri V; Conte P; Paolucci P; Dominici M
Stem Cells; 2015 Mar; 33(3):859-69. PubMed ID: 25420617
[TBL] [Abstract][Full Text] [Related]
4. A therapeutic strategy for metastatic malignant fibrous histiocytoma through mesenchymal stromal cell-mediated TRAIL production.
Lee HJ; Yang HM; Choi YS; Park SH; Moon SH; Lee YS; Sung YC; Kim SJ
Ann Surg; 2013 May; 257(5):952-60. PubMed ID: 23108118
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy.
Yuan Z; Kolluri KK; Sage EK; Gowers KH; Janes SM
Cytotherapy; 2015 Jul; 17(7):885-96. PubMed ID: 25888191
[TBL] [Abstract][Full Text] [Related]
7. pIL6-TRAIL-engineered umbilical cord mesenchymal/stromal stem cells are highly cytotoxic for myeloma cells both in vitro and in vivo.
Cafforio P; Viggiano L; Mannavola F; Pellè E; Caporusso C; Maiorano E; Felici C; Silvestris F
Stem Cell Res Ther; 2017 Sep; 8(1):206. PubMed ID: 28962646
[TBL] [Abstract][Full Text] [Related]
8. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy.
Kim SM; Oh JH; Park SA; Ryu CH; Lim JY; Kim DS; Chang JW; Oh W; Jeun SS
Stem Cells; 2010 Dec; 28(12):2217-28. PubMed ID: 20945331
[TBL] [Abstract][Full Text] [Related]
9. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
10. TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo.
Mueller LP; Luetzkendorf J; Widder M; Nerger K; Caysa H; Mueller T
Cancer Gene Ther; 2011 Apr; 18(4):229-39. PubMed ID: 21037557
[TBL] [Abstract][Full Text] [Related]
11. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
12. In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells.
Ciavarella S; Grisendi G; Dominici M; Tucci M; Brunetti O; Dammacco F; Silvestris F
Br J Haematol; 2012 Jun; 157(5):586-98. PubMed ID: 22420897
[TBL] [Abstract][Full Text] [Related]
13. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy.
Grisendi G; Bussolari R; Cafarelli L; Petak I; Rasini V; Veronesi E; De Santis G; Spano C; Tagliazzucchi M; Barti-Juhasz H; Scarabelli L; Bambi F; Frassoldati A; Rossi G; Casali C; Morandi U; Horwitz EM; Paolucci P; Conte P; Dominici M
Cancer Res; 2010 May; 70(9):3718-29. PubMed ID: 20388793
[TBL] [Abstract][Full Text] [Related]
14. Platelet-derived growth factor receptor beta inhibition increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity: imatinib and TRAIL dual therapy.
Wang Y; Mandal D; Wang S; Kleinerman ES; Pollock RE; Lev D; Hayes-Jordan A
Cancer; 2010 Aug; 116(16):3892-902. PubMed ID: 20564078
[TBL] [Abstract][Full Text] [Related]
15. Activated human mesenchymal stem/stromal cells suppress metastatic features of MDA-MB-231 cells by secreting IFN-β.
Yoon N; Park MS; Shigemoto T; Peltier G; Lee RH
Cell Death Dis; 2016 Apr; 7(4):e2191. PubMed ID: 27077807
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic variant of TSP-1 targets tumor cells in glioblastomas.
Choi SH; Tamura K; Khajuria RK; Bhere D; Nesterenko I; Lawler J; Shah K
Mol Ther; 2015 Feb; 23(2):235-43. PubMed ID: 25358253
[TBL] [Abstract][Full Text] [Related]
17. USP6 Confers Sensitivity to IFN-Mediated Apoptosis through Modulation of TRAIL Signaling in Ewing Sarcoma.
Henrich IC; Young R; Quick L; Oliveira AM; Chou MM
Mol Cancer Res; 2018 Dec; 16(12):1834-1843. PubMed ID: 30131449
[TBL] [Abstract][Full Text] [Related]
18. Claudin-7 suppresses the cytotoxicity of TRAIL-expressing mesenchymal stem cells in H460 human non-small cell lung cancer cells.
Xia P; Wang W; Bai Y
Apoptosis; 2014 Mar; 19(3):491-505. PubMed ID: 24242915
[TBL] [Abstract][Full Text] [Related]
19. ML327 induces apoptosis and sensitizes Ewing sarcoma cells to TNF-related apoptosis-inducing ligand.
Rellinger EJ; Padmanabhan C; Qiao J; Appert A; Waterson AG; Lindsley CW; Beauchamp RD; Chung DH
Biochem Biophys Res Commun; 2017 Sep; 491(2):463-468. PubMed ID: 28716733
[TBL] [Abstract][Full Text] [Related]
20. A functional, new short isoform of death receptor 4 in Ewing's sarcoma cell lines may be involved in TRAIL sensitivity/resistance mechanisms.
Picarda G; Surget S; Guiho R; Téletchéa S; Berreur M; Tirode F; Pellat-Deceunynck C; Heymann D; Trichet V; Rédini F
Mol Cancer Res; 2012 Mar; 10(3):336-46. PubMed ID: 22258765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
